ClinicalTrials.gov record
Active, not recruiting Phase 2 Interventional

Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors

ClinicalTrials.gov ID: NCT02574728

Public ClinicalTrials.gov record NCT02574728. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 8, 2026, 8:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

AflacST1502: A Phase II Study of Sirolimus in Combination With Metronomic Chemotherapy in Children With Recurrent and/or Refractory Solid and CNS Tumors

Study identification

NCT ID
NCT02574728
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
Emory University
Other
Enrollment
46 participants

Conditions and interventions

Conditions

Interventions

  • Celecoxib Drug
  • Cyclophosphamide Drug
  • Etoposide Drug
  • Sirolimus Drug

Drug

Eligibility (public fields only)

Age range
12 Months to 30 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
May 31, 2015
Primary completion
May 31, 2026
Completion
May 31, 2026
Last update posted
Mar 1, 2026

2015 – 2026

United States locations

U.S. sites
6
U.S. states
5
U.S. cities
5
Facility City State ZIP Site status
Phoenix Children's Hospital Phoenix Arizona 85016
Nemours/Alfred I. duPont Hospital for Children Wilmington Delaware 19803
Children's Healthcare of Atlanta-Egleston Atlanta Georgia 30322
Children's Healthcare of Atlanta, Scottish Rite Atlanta Georgia 30342
Children's Mercy Hospital Kansas City Missouri 64108
University of Virginia Health System Charlottesville Virginia 22908

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02574728, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Mar 1, 2026 · Synced May 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02574728 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →